{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:02:55Z","timestamp":1787655775311,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The PROteKT study tested the hypothesis that rosuvastatin can inhibit aminoglycoside-induced nephrotoxicity in children with Cystic Fibrosis (CF). This open label, parallel group, randomised controlled trial recruited children and young people aged 6 to 18 years with CF at 13 paediatric CF treatment centres in the UK. Participants were randomised equally to either receive oral rosuvastatin (10\u2009mg once daily) or no intervention (control) throughout clinically indicated treatment with intravenous tobramycin. The primary outcome was the difference between the groups in mean fold-change in urinary Kidney Injury Molecule-1 (KIM-1). Fifty (rosuvastatin n\u2009=\u200923, control n\u2009=\u200927) participants were recruited between May 2015 and January 2017. Primary outcome data was available for 88% (rosuvastatin n\u2009=\u200920, control n\u2009=\u200924). The estimated mean treatment difference in the geometric mean-fold change of normalised KIM-1 was 1.08 (95% CI 0.87\u20131.35, p\u2009=\u20090.48). In total there were 12 adverse reactions, all mild, reported by five participants randomised to rosuvastatin, and one serious adverse event in each group. Whilst no protective effect of rosuvastatin was seen, there was a lower than expected level of nephrotoxicity in the cohort. Therefore, we can neither confirm nor refute the hypothesis that rosuvastatin protects against aminoglycoside nephrotoxicity.<\/jats:p>","DOI":"10.1038\/s41598-020-58790-1","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T11:02:47Z","timestamp":1580814167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-7425","authenticated-orcid":false,"given":"Stephen J.","family":"McWilliam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rosala-Hallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Greenhalf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind L.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"58790_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1106\/4WVW-ACLD-EKV6-MBJJ","volume":"14","author":"CA Robinson","year":"2001","unstructured":"Robinson, C. A. & Kuhn, R. J. Management of pulmonary disease in patients with cystic fibrosis. J. Pharm. Pract. 14, 207\u2013227 (2001).","journal-title":"J. Pharm. Pract."},{"key":"58790_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/thx.2006.067595","volume":"62","author":"C Bertenshaw","year":"2007","unstructured":"Bertenshaw, C., Watson, A. R., Lewis, S. & Smyth, A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 62, 541\u2013545 (2007).","journal-title":"Thorax"},{"key":"58790_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00467-016-3471-9","volume":"32","author":"JA Saban","year":"2017","unstructured":"Saban, J. A., Pizzi, M., Caldwell, J., Palijan, A. & Zappitelli, M. Previous aminoglycoside use and acute kidney injury risk in non-critically ill children. Pediatr. Nephrol. 32, 173\u2013179 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"58790_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1136\/thx.2007.088757","volume":"63","author":"A Smyth","year":"2008","unstructured":"Smyth, A. et al. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 63, 532\u2013535 (2008).","journal-title":"Thorax"},{"key":"58790_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jcf.2014.03.005","volume":"13","author":"KJ Downes","year":"2014","unstructured":"Downes, K. J. et al. Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis. J. Cyst. Fibros. 13, 435\u2013441 (2014).","journal-title":"J. Cyst. Fibros."},{"key":"58790_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00467-015-3097-3","volume":"30","author":"KJ Downes","year":"2015","unstructured":"Downes, K. J. et al. Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis. Pediatr. Nephrol. 30, 1879\u20131888 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"58790_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ppul.20138","volume":"39","author":"M Al-Aloul","year":"2005","unstructured":"Al-Aloul, M. et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr. Pulmonol. 39, 15\u201320 (2005).","journal-title":"Pediatr. Pulmonol."},{"key":"58790_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1128\/AAC.31.4.594","volume":"31","author":"SS Pedersen","year":"1987","unstructured":"Pedersen, S. S., Jensen, T., Osterhammel, D. & Osterhammel, P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob. Agents Chemother. 31, 594\u2013599 (1987).","journal-title":"Antimicrob. Agents Chemother."},{"key":"58790_CR9","doi-asserted-by":"crossref","unstructured":"Stehling, F., B\u00fcscher, R., Grosse-Onnebrink, J., Hoyer, P. F. & Mellies, U. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients. Pulm. Med. 2017 (2017).","DOI":"10.1155\/2017\/2602653"},{"key":"58790_CR10","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00467-016-3533-z","volume":"32","author":"SJ McWilliam","year":"2017","unstructured":"McWilliam, S. J., Antoine, D. J., Smyth, R. L. & Pirmohamed, M. Aminoglycoside-induced nephrotoxicity in children. Pediatr. Nephrol. 32, 2015\u20132025 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"58790_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1074\/jbc.M109959200","volume":"277","author":"C Schmitz","year":"2002","unstructured":"Schmitz, C. et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J. Biol. Chem. 277, 618\u2013622 (2002).","journal-title":"J. Biol. Chem."},{"key":"58790_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(99)08347-6","volume":"355","author":"A Khwaja","year":"2000","unstructured":"Khwaja, A., Connolly, J. O. & Hendry, B. M. Prenylation inhibitors in renal disease. Lancet 355, 741\u2013744 (2000).","journal-title":"Lancet"},{"key":"58790_CR13","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1097\/01.ASN.0000138236.82706.EE","volume":"15","author":"JE Sidaway","year":"2004","unstructured":"Sidaway, J. E. et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol. 15, 2258\u20132265 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"58790_CR14","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1097\/01.ASN.0000136778.32499.05","volume":"15","author":"A Verhulst","year":"2004","unstructured":"Verhulst, A., D\u2019Haese, P. C. & De Broe, M. E. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J. Am. Soc. Nephrol. 15, 2249\u20132257 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"58790_CR15","first-page":"36","volume":"5","author":"V Chinnapa Reddy","year":"2012","unstructured":"Chinnapa Reddy, V. et al. Effect of simvastatin in gentamicin induced nephrotoxicity in albino rats. Asian J. Pharm. Clin. Res. 5, 36\u201340 (2012).","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"58790_CR16","first-page":"1181","volume":"22","author":"M Jabbari","year":"2011","unstructured":"Jabbari, M., Rostami, Z., Jenabi, A., Bahrami, A. & Mooraki, A. Simvastatin ameliorates gentamicin-induced renal injury in rats. Saudi J. Kidney Dis. Transpl. 22, 1181\u20131186 (2011).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"58790_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1113\/EP085571","volume":"101","author":"K Jaikumkao","year":"2016","unstructured":"Jaikumkao, K. et al. Atorvastatin improves renal organic anion transporter 3 and renal function in gentamicin-induced nephrotoxicity in rats. Exp. Physiol. 101, 743\u2013753 (2016).","journal-title":"Exp. Physiol."},{"issue":"10","key":"58790_CR18","doi-asserted-by":"publisher","first-page":"e0164528","DOI":"10.1371\/journal.pone.0164528","volume":"11","author":"Krit Jaikumkao","year":"2016","unstructured":"Jaikumkao, K. et al. Amelioration of renal inflammation, endoplasmic reticulum stress and apoptosis underlies the protective effect of low dosage of atorvastatin in gentamicin-induced nephrotoxicity. PLoS One 11 (2016).","journal-title":"PLOS ONE"},{"key":"58790_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/08860220902835863","volume":"31","author":"E Ozbek","year":"2009","unstructured":"Ozbek, E. et al. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kB pathways. Ren. Fail. 31, 382\u2013392 (2009).","journal-title":"Ren. Fail."},{"key":"58790_CR20","doi-asserted-by":"crossref","unstructured":"Selim, A., khalaf, M. M., Gad, A. M. & Abd El-Raouf, O. M. Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin-induced renal injury in rats. J. Biochem. Mol. Toxicol. 31 (2017).","DOI":"10.1002\/jbt.21957"},{"key":"58790_CR21","unstructured":"AstraZeneca UK Limited. Crestor 10\u2009mg film-coated tablets - Summary of Product Characteristics. Available at, www.medicines.org.uk\/emc\/product\/7559\/smpc, (Accessed: 4th December 2019) (2019)."},{"key":"58790_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum, J. A. et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements 2, 1\u2013138 (2012).","journal-title":"Kidney International Supplements"},{"key":"58790_CR23","doi-asserted-by":"crossref","unstructured":"McWilliam, S. J., Antoine, D. J., Jorgensen, A. L., Smyth, R. L. & Pirmohamed, M. Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin. Sci. Rep. 8 (2018).","DOI":"10.1038\/s41598-018-23466-4"},{"key":"58790_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1177\/0192623308315832","volume":"36","author":"J Zhang","year":"2008","unstructured":"Zhang, J. et al. Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidney of Gentamicin-, Mercury-, or Chromium-Treated Rats: Relationship to Renal Distributions of iNOS and Nitrotyrosine. Toxicol. Pathol. 36, 397\u2013409 (2008).","journal-title":"Toxicol. Pathol."},{"issue":"8","key":"58790_CR25","doi-asserted-by":"publisher","first-page":"e43809","DOI":"10.1371\/journal.pone.0043809","volume":"7","author":"Stephen J. McWilliam","year":"2012","unstructured":"McWilliam, S. J. et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: A proof-of-concept study. PLoS One 7 (2012).","journal-title":"PLoS ONE"},{"key":"58790_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ppul.22795","volume":"49","author":"T Lahiri","year":"2014","unstructured":"Lahiri, T., Guillet, A., Diehl, S. & Ferguson, M. High-dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis. Pediatr. Pulmonol. 49, 148\u2013153 (2014).","journal-title":"Pediatr. Pulmonol."},{"key":"58790_CR27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nbt.1623","volume":"28","author":"VS Vaidya","year":"2010","unstructured":"Vaidya, V. S. et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol. 28, 478\u2013485 (2010).","journal-title":"Nat. Biotechnol."},{"key":"58790_CR28","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1016\/S0021-9258(18)82217-7","volume":"268","author":"L Kjeldsen","year":"1993","unstructured":"Kjeldsen, L., Johnsen, A. H., Sengelov, H. & Borregaard, N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268, 10425\u201310432 (1993).","journal-title":"J. Biol. Chem."},{"key":"58790_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.ajkd.2009.07.020","volume":"54","author":"M Haase","year":"2009","unstructured":"Haase, M. et al. Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis. Am. J. Kidney Dis. 54, 1012\u20131024 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"58790_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2217\/bmm.14.36","volume":"8","author":"SJ Mcwilliam","year":"2014","unstructured":"Mcwilliam, S. J. et al. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark. Med. 8, 1189\u20131197 (2014).","journal-title":"Biomark. Med."},{"key":"58790_CR31","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1097\/01.ASN.0000143720.71748.79","volume":"15","author":"R Agarwal","year":"2004","unstructured":"Agarwal, R. Statin induced proteinuria: Renal injury or renoprotection? J. Am. Soc. Nephrol. 15, 2502\u20132503 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"58790_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jcf.2015.07.012","volume":"15","author":"AP Prayle","year":"2016","unstructured":"Prayle, A. P. et al. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. J. Cyst. Fibros. 15, 510\u2013517 (2016).","journal-title":"J. Cyst. Fibros."},{"key":"58790_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00228-014-1800-0","volume":"71","author":"BK Birmingham","year":"2015","unstructured":"Birmingham, B. K. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur. J. Clin. Pharmacol. 71, 329\u2013340 (2015).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"58790_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jacl.2015.07.011","volume":"9","author":"MJAM Braamskamp","year":"2015","unstructured":"Braamskamp, M. J. A. M. et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. J. Clin. Lipidol. 9, 741\u2013750 (2015).","journal-title":"J. Clin. Lipidol."},{"key":"58790_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0009-9236(02)17633-8","volume":"73","author":"KJ Cooper","year":"2003","unstructured":"Cooper, K. J. et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 73, 322\u2013329 (2003).","journal-title":"Clin. Pharmacol. Ther."},{"key":"58790_CR36","unstructured":"Paediatric Formulary Committee. BNF for children. MeReC Extra Available at, www.medicinescomplete.com, (Accessed: 4th December 2019) (2005)."},{"key":"58790_CR37","doi-asserted-by":"crossref","unstructured":"Seo, M. S. et al. Effect of treatment on urinary kidney injury molecule-1 in IgA nephropathy. BMC Nephrol. 14 (2013).","DOI":"10.1186\/1471-2369-14-139"},{"key":"58790_CR38","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1515\/cclm-2014-0655","volume":"53","author":"JAM De Carvalho","year":"2015","unstructured":"De Carvalho, J. A. M. et al. Evaluation of the diagnostic characteristics of urinary kidney injury molecule 1 (uKIM-1) and uKIM-1\/creatinine ratio in the assessment of incipient diabetic kidney disease. Clin. Chem. Lab. Med. 53, e51\u2013e54 (2015).","journal-title":"Clin. Chem. Lab. Med."},{"key":"58790_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jcf.2017.01.002","volume":"16","author":"R Szczesniak","year":"2017","unstructured":"Szczesniak, R., Heltshe, S. L., Stanojevic, S. & Mayer-Hamblett, N. Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher. Journal of Cystic Fibrosis 16, 318\u2013326 (2017).","journal-title":"Journal of Cystic Fibrosis"},{"key":"58790_CR40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ki.2010.165","volume":"78","author":"SS Waikar","year":"2010","unstructured":"Waikar, S. S., Sabbisetti, V. S. & Bonventre, J. V. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 78, 486\u2013494 (2010).","journal-title":"Kidney Int."}],"updated-by":[{"DOI":"10.1038\/s41598-020-61783-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58790-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T15:05:11Z","timestamp":1672671911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58790-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["58790"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-58790-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-020-61783-9","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"8 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1796"}}